West Pharmaceutical HR chief sells 8,135 shares

WEST PHARMACEUTICAL SERVICES INC (WST) reported that Annette F. Favorite, its Sr.

Rhea-AI Filing Summary

WEST PHARMACEUTICAL SERVICES INC (WST) reported that Annette F. Favorite, its Sr. VP & Chief HR Officer, exercised employee stock options for 8,135 shares of common stock on September 8, 2026, at exercise prices of $83.47 and $89.64, and sold all 8,135 shares at a weighted average price of $340.81 per share. The options exercised were from awards granted in 2017 and 2018 that vested in four annual installments, and she continues to hold 7,524 option shares from the 2018 grant. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Exercise and Sale: 8,135 shares ($2.08M approx. pre-tax spread)

Exercise and Sale 9 txns

Insider Favorite Annette F

Role Sr. VP & Chief HR Officer

Sold 8,135 shs ($2.77M)

Approx. gross sale proceeds $2.77M

Approx. exercise cost $694K

Approx. pre-tax spread $2.08M

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy) F2	2,817	$0.00	$0.00
Exercise	Stock Options (Right to Buy) F2	2,818	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F3	2,500	$0.00	$0.00
Exercise	Common Stock	2,817	$83.47	$235K
Sale	Common Stock F1	2,817	$340.81	$960K
Exercise	Common Stock	2,818	$83.47	$235K
Sale	Common Stock F1	2,818	$340.81	$960K
Exercise	Common Stock	2,500	$89.64	$224K
Sale	Common Stock F1	2,500	$340.81	$852K

Holdings After Transaction: Stock Options (Right to Buy) — 0 contracts (Direct); Stock Option (Right to Buy) — 7,524 contracts (Direct); Common Stock — 16,844.5548 shares (Direct)

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price resulting in such weighted average price.
2. F2. This award granted on February 21, 2017 vested in four equal annual installments beginning on February 21, 2018.
3. F3. This award granted on February 20, 2018 vested in four equal annual installments beginning on February 20, 2019.

Key Figures

Options exercised: 8,135 shares Shares sold: 8,135 shares Weighted average sale price: $340.81 per share +3 more

6 metrics

Options exercised 8,135 shares Employee stock options converted into common stock on September 8, 2026

Shares sold 8,135 shares Common stock sold on September 8, 2026 following option exercises

Weighted average sale price $340.81 per share Price for common stock sales on September 8, 2026

Option exercise price (2017 grant) $83.47 per share Options granted on February 21, 2017 and exercised into 5,635 shares

Option exercise price (2018 grant) $89.64 per share Options granted on February 20, 2018 and exercised into 2,500 shares

Remaining options from 2018 grant 7,524 shares Unexercised employee stock options after the reported transactions

Key Terms

weighted average price, vested, annual installments

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vested financial

"This award granted on February 21, 2017 vested in four equal annual installments"

annual installments financial

"vested in four equal annual installments beginning on February 20, 2019."

FAQ

Who is the insider trading in WST shares in this Form 4?

The transactions involve Annette F. Favorite, who serves as Sr. VP & Chief HR Officer of WEST PHARMACEUTICAL SERVICES INC (WST). The filing reports her option exercises and related sales on September 8, 2026.

How many WEST PHARMACEUTICAL SERVICES INC (WST) shares did the insider sell?

Annette F. Favorite sold 8,135 shares of WEST PHARMACEUTICAL SERVICES INC common stock on September 8, 2026, through three separate sale transactions reported in the Form 4.

At what price were the WST shares sold in this Form 4 transaction?

The common shares were sold at a weighted average price of $340.81 per share. A footnote states that this is a weighted average and that full information on the individual sale prices is available upon request.

What option exercise prices are disclosed for the WST insider in this Form 4?

The Form 4 shows exercises of employee stock options with exercise prices of $83.47 per share from awards granted on February 21, 2017, and $89.64 per share from an award granted on February 20, 2018.

How many WEST PHARMACEUTICAL SERVICES INC options does the insider still hold after these transactions?

After exercising 2,500 options from the 2018 grant, Annette F. Favorite continues to hold 7,524 option shares from that grant, according to the post-transaction option balance reported in the Form 4.

Were the WST insider transactions made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is associated with these reported transactions by Annette F. Favorite.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 05:37 PM Accepted by SEC EDGAR 09/10/2026 - 05:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Favorite Annette F

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP & Chief HR Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		M		2,817	A	$83.47	19,661.5548	D
Common Stock	09/08/2026		S		2,817	D	$340.81(1)	16,844.5548	D
Common Stock	09/08/2026		M		2,818	A	$83.47	19,662.5548	D
Common Stock	09/08/2026		S		2,818	D	$340.81(1)	16,844.5548	D
Common Stock	09/08/2026		M		2,500	A	$89.64	19,344.5548	D
Common Stock	09/08/2026		S		2,500	D	$340.81(1)	16,844.5548	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$83.47	09/08/2026		M			2,817	(2)	02/21/2027	Common Stock	2,817	$0	2,818	D
Stock Options (Right to Buy)	$83.47	09/08/2026		M			2,818	(2)	02/21/2027	Common Stock	2,818	$0	0	D
Stock Option (Right to Buy)	$89.64	09/08/2026		M			2,500	(3)	02/20/2028	Common Stock	2,500	$0	7,524	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price resulting in such weighted average price.

2. This award granted on February 21, 2017 vested in four equal annual installments beginning on February 21, 2018.

3. This award granted on February 20, 2018 vested in four equal annual installments beginning on February 20, 2019.

Remarks:

	/s/ Louis Lalli, as an agent for Annette Favorite	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)